TR200003281T2 - CD-23'e karşı antikorlar, bunların türevleri ve terapötik kullanımları. - Google Patents

CD-23'e karşı antikorlar, bunların türevleri ve terapötik kullanımları.

Info

Publication number
TR200003281T2
TR200003281T2 TR2000/03281T TR200003281T TR200003281T2 TR 200003281 T2 TR200003281 T2 TR 200003281T2 TR 2000/03281 T TR2000/03281 T TR 2000/03281T TR 200003281 T TR200003281 T TR 200003281T TR 200003281 T2 TR200003281 T2 TR 200003281T2
Authority
TR
Turkey
Prior art keywords
antibodies
derivatives
therapeutic uses
rii
bind
Prior art date
Application number
TR2000/03281T
Other languages
English (en)
Inventor
Marcel Paul Bonnefoy Jean-Yves
James Crowe Scott
Henry Ellis Jonathan
Timothy Rapson Nicholas
Shearin Jean
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of TR200003281T2 publication Critical patent/TR200003281T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Bulus, CD23 (FC RII) tip II molekülüne baglanan antikorlara, özellikle, 1x10 Ka Mo1 den daha büyük ya da esit bir afinite sabiti ile vasiflanan CD23 (FC RII) tip II molekülüne baglanan antikorlari kapsayan degistirilmis antikorlara, bu antikorlarin hazirlanmasi, bu antikorlari ihtiva eden farmasötik bilesimler ve bunlarin terapide, özellikle otoimün ve iltihapli bozukluklarin tedavisinde kullanimlarina iliskindir.
TR2000/03281T 1998-05-09 1999-05-07 CD-23'e karşı antikorlar, bunların türevleri ve terapötik kullanımları. TR200003281T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9809839.5A GB9809839D0 (en) 1998-05-09 1998-05-09 Antibody

Publications (1)

Publication Number Publication Date
TR200003281T2 true TR200003281T2 (tr) 2001-03-21

Family

ID=10831668

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/03281T TR200003281T2 (tr) 1998-05-09 1999-05-07 CD-23'e karşı antikorlar, bunların türevleri ve terapötik kullanımları.

Country Status (25)

Country Link
US (1) US7008623B1 (tr)
EP (1) EP1076701A1 (tr)
JP (1) JP2002514421A (tr)
KR (1) KR20010043470A (tr)
CN (1) CN1308676A (tr)
AP (1) AP1547A (tr)
AU (1) AU763491B2 (tr)
BR (1) BR9910327A (tr)
CA (1) CA2328606A1 (tr)
EA (1) EA200001041A1 (tr)
EE (1) EE200000658A (tr)
GB (1) GB9809839D0 (tr)
HR (1) HRP20000762A2 (tr)
HU (1) HUP0102005A3 (tr)
ID (1) ID28088A (tr)
IL (1) IL139384A0 (tr)
IS (1) IS5696A (tr)
NO (1) NO20005632L (tr)
NZ (1) NZ507879A (tr)
PL (1) PL344019A1 (tr)
SK (1) SK16762000A3 (tr)
TR (1) TR200003281T2 (tr)
WO (1) WO1999058679A1 (tr)
YU (1) YU69000A (tr)
ZA (1) ZA200006312B (tr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
WO2002030986A2 (en) 2000-10-13 2002-04-18 Biogen, Inc. HUMANIZED ANTI-LT-β-R ANTIBODIES
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
AU2003248782A1 (en) * 2002-07-01 2004-01-19 Biogen Idec Ma Inc. Humanized anti-lymphotoxin beta receptor antibodies
TWI323265B (en) 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
JP5068072B2 (ja) 2003-06-27 2012-11-07 バイオジェン・アイデック・エムエイ・インコーポレイテッド 連結ペプチドを含む改変された結合分子
CA2434668A1 (en) 2003-07-04 2005-01-04 Laurence Mulard Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
EP2135619A1 (en) * 2003-12-10 2009-12-23 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
CN1980957A (zh) 2004-03-23 2007-06-13 比奥根艾迪克Ma公司 受体偶联剂及其治疗用途
US20060246075A1 (en) * 2004-09-29 2006-11-02 Marc Mercken Anti-amyloid antibodies, compositions, methods and uses
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
BRPI0618705B8 (pt) * 2005-11-14 2021-05-25 Labrys Biologics Inc anticorpos antagonistas humanizados direcionados contra peptídeo relacionado ao gene da calcitonina, composição farmacêutica e uso dos mesmos
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
EP1804172B1 (en) * 2005-12-20 2021-08-11 Roche Diagnostics GmbH PCR elbow determination using curvature analysis of a double sigmoid
US7680868B2 (en) * 2005-12-20 2010-03-16 Roche Molecular Systems, Inc. PCR elbow determination by use of a double sigmoid function curve fit with the Levenburg-Marquardt algorithm and normalization
WO2009043051A2 (en) * 2007-09-27 2009-04-02 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
CN104650235A (zh) 2007-11-30 2015-05-27 葛兰素集团有限公司 抗原结合构建体
CA2716424C (en) 2008-03-04 2015-04-28 Pfizer Limited Methods of treating chronic pain
CL2009001076A1 (es) 2008-05-06 2010-09-24 Glaxo Group Ltd Nanoparticulas que comprende una sustancia formadora de particulas y una proteina; composicion que comprende dichas nanoparticulas; procedimiento para suministrar una proteina a traves de la membrana hematoencefalica; uso de la composicion para profilaxis o tratar enfermedades del sistema nervioso central.
WO2010097385A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
WO2010097386A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
JP2012518400A (ja) 2009-02-24 2012-08-16 グラクソ グループ リミテッド 多価および／または複数特異的ｒａｎｋｌ結合性構築物
WO2010115786A1 (en) 2009-04-01 2010-10-14 Glaxo Group Limited Anti-il-23 immunoglobulins
US20120058116A1 (en) 2009-04-24 2012-03-08 Andrew Beaton Fgfr1c antibody combinations
RU2535074C2 (ru) 2009-08-28 2014-12-10 Лэйбрис Байолоджикс, Инк. Способы лечения висцеральной боли путем введения антител-антагонистов, направленных против пептида, связанного с геном кальцитонина
FR2957598B1 (fr) 2010-03-17 2015-12-04 Lfb Biotechnologies Nouveau peptide signal, et son utilisation pour la production de proteines recombinantes
UY33743A (es) 2010-11-23 2012-06-29 Glaxo Group Ltd Proteínas de unión a antígenos
JP2014501725A (ja) 2010-11-24 2014-01-23 グラクソ グループ リミテッド Ｈｇｆを標的とする多特異的抗原結合タンパク質
US8974782B2 (en) 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies
PT3415531T (pt) 2011-05-27 2023-09-12 Glaxo Group Ltd Proteínas de ligação a bcma (cd269/tnfrsf17
EP2888279A1 (en) 2012-08-22 2015-07-01 Glaxo Group Limited Anti lrp6 antibodies
US10176293B2 (en) 2012-10-02 2019-01-08 Roche Molecular Systems, Inc. Universal method to determine real-time PCR cycle threshold values
CA2902831C (en) 2013-03-15 2023-04-25 Glaxosmithkline Intellectual Property Development Limited Anti-lag-3 binding proteins
JP6440036B2 (ja) * 2013-07-10 2018-12-19 オンコノックス エーピーエス 抗β２−グリコプロテインＩ抗体及びその治療的用法
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
RS65360B1 (sr) 2014-03-21 2024-04-30 Teva Pharmaceuticals Int Gmbh Antagonistička antitela specifična za peptid genski srodan kalcitoninu i postupci njihove upotrebe
WO2017037203A1 (en) 2015-09-02 2017-03-09 Immutep S.A.S. Anti-LAG-3 Antibodies
US10479827B2 (en) 2016-05-31 2019-11-19 Sysmex Corporation Monoclonal antibody reacting with glycopeptide, and use thereof
JP6935184B2 (ja) * 2016-05-31 2021-09-15 シスメックス株式会社 糖ペプチドと反応するモノクローナル抗体およびその用途
WO2017220990A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 antibodies
MX2019003337A (es) 2016-09-23 2019-09-26 Teva Pharmaceuticals Int Gmbh Tratamiento para migraña refractaria.
KR20220026585A (ko) 2019-06-26 2022-03-04 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Il1rap 결합 단백질
CN112552403A (zh) * 2020-12-25 2021-03-26 南京英瀚斯生物科技有限公司 一种人源抗人CD23抗体的Fab片段、药物组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU673499B2 (en) 1991-07-25 1996-11-14 Biogen Idec Inc. Recombinant antibodies for human therapy
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
EP0788514A1 (en) * 1994-10-25 1997-08-13 Glaxo Group Limited Binding agents for treatment of inflammatory, autoimmune or allergic diseases
US6011138A (en) * 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies

Also Published As

Publication number Publication date
IS5696A (is) 2000-10-31
HUP0102005A3 (en) 2003-10-28
BR9910327A (pt) 2001-01-30
JP2002514421A (ja) 2002-05-21
AP2000001983A0 (en) 2000-12-31
PL344019A1 (en) 2001-09-24
NO20005632D0 (no) 2000-11-08
EA200001041A1 (ru) 2001-06-25
US7008623B1 (en) 2006-03-07
KR20010043470A (ko) 2001-05-25
NO20005632L (no) 2001-01-08
SK16762000A3 (sk) 2001-07-10
CN1308676A (zh) 2001-08-15
AU3836799A (en) 1999-11-29
EE200000658A (et) 2002-04-15
IL139384A0 (en) 2001-11-25
GB9809839D0 (en) 1998-07-08
WO1999058679A1 (en) 1999-11-18
HUP0102005A2 (hu) 2001-10-28
ID28088A (id) 2001-05-03
HRP20000762A2 (en) 2001-06-30
CA2328606A1 (en) 1999-11-18
NZ507879A (en) 2004-02-27
ZA200006312B (en) 2003-02-26
YU69000A (sh) 2003-08-29
AP1547A (en) 2006-01-13
AU763491B2 (en) 2003-07-24
EP1076701A1 (en) 2001-02-21

Similar Documents

Publication Publication Date Title
TR200003281T2 (tr) CD-23'e karşı antikorlar, bunların türevleri ve terapötik kullanımları.
DE69530763D1 (de) Antikörper gegen e-selektin
ATE364699T1 (de) Humanisierte antikörper gegen humanes gp39, zusammensetzungen die diese enthalten und deren therapeutische verwendungen
DE60220719D1 (de) Antikörper gegen das muc18-antigen
DE69840699D1 (de) Heregulin varianten
DE69637781D1 (de) Für den il-13 rezeptor spezifische chimäre proteine und ihre verwendungen
DK0910647T3 (da) Human DNase i hyperaktive varianter
WO2004019878A3 (en) Adzymes and uses thereof
TR199902562T2 (tr) Degistirilmis TNF alfa molekülleri
DE69432412T2 (de) Gelonin und einen antikörper entahltende immuntoxine
DE60040753D1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
ATE396205T1 (de) Die verwendung von peptiden von il-2 und peptid- derivaten als therapeutische wirkstoffe
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
BR9910860A (pt) Uso de ciclosporinas no tratamento de doenças auto-imunes inflamatórias
PT877803E (pt) Receptor da proteina ob e composicoes e metodos afins
ATE449847T1 (de) Hepatitis c rezeptorprotein cd81
BR0317161A (pt) Moléculas de ligação nogo a e uso farmacêutico das mesmas
DE60037978D1 (de) Interferon ähnliche moleküle, und deren verwendungen
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
DE69920681D1 (de) Humaner k+ ionenkanal und therapeutische verwendungen davon
BRPI0414174A (pt) moléculas de ligação nogo-a e o uso farmacêutico das mesmas
DK1039931T3 (da) Multivalente rekombinante antistoffer til at behandle HRV infektioner
DK0811068T3 (da) Humane DNase I varianter
TR199700842T1 (tr) Insan DNase I Varyantlari.
MX9708830A (es) Compuestos de tetralin con actividad de resistencia a varios farmacos.